

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

FITC anti-human CD11b

RRID:AB_2561703

Type: Antibody

Proper Citation

BioLegend Cat# 301330, RRID:AB_2561703

Antibody Information

URL: http://antibodyregistry.org/AB_2561703

Proper Citation: BioLegend Cat# 301330, RRID:AB_2561703

Target Antigen: CD11b

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone ICRF44

Antibody ID: AB_2561703

Vendor: BioLegend

Catalog Number: 301330

Alternative Catalog Numbers: 301329

Record Creation Time: 20250820T050600+0000

Record Last Update: 20250820T204706+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD11b.

No alerts have been found for FITC anti-human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Zhou X, et al. (2025) Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity. *Cell reports. Medicine*, 6(4), 102079.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. *STAR protocols*, 6(2), 103742.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. *STAR protocols*, 6(2), 103810.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. *Med (New York, N.Y.)*, 100804.

Zhang Z, et al. (2024) Sirtuin 2 regulates neutrophil functions through NAD⁺ synthesis pathway in virus infection. *iScience*, 27(7), 110184.

Shen J, et al. (2024) Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. *Cell stem cell*, 31(7), 1003.

Huang S, et al. (2024) Glioblastoma stem cell-derived exosomal miR-374b-3p promotes tumor angiogenesis and progression through inducing M2 macrophages polarization. *iScience*, 27(3), 109270.

Ji RJ, et al. (2024) Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia. *Cell stem cell*, 31(11), 1650.

Long J, et al. (2023) A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. *Cell reports. Medicine*, 4(11), 101286.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. *iScience*, 26(10), 107952.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer cell*, 41(4), 693.

Tian L, et al. (2023) C-Myc-induced hypersialylation of small cell lung cancer facilitates pro-tumoral phenotypes of macrophages. *iScience*, 26(10), 107771.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. *iScience*, 25(9), 104859.

Zhao M, et al. (2022) Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells. *Journal of oncology*, 2022, 3345536.

Takano T, et al. (2022) Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. *Cell reports. Medicine*, 3(5), 100631.

Yan K, et al. (2022) Transcriptomic heterogeneity of cultured ADSCs corresponds to embolic risk in the host. *iScience*, 25(8), 104822.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. *Cell reports. Medicine*, 2(11), 100449.

Marjanovic ND, et al. (2020) Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. *Cancer cell*, 38(2), 229.

Friebel E, et al. (2020) Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invasive Leukocytes. *Cell*, 181(7), 1626.

Zhu Y, et al. (2019) Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. *Cell stem cell*, 25(4), 542.